CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2023-03, Vol.16 (1), p.18-18, Article 18
Main Authors: Huang, Qiusha, Zhang, Xiao-Hui, Liu, Delong
Format: Article
Language:English
Subjects:
Antigens
Antimitotic agents
Antineoplastic agents
Biomarkers
Cancer
CAR T
Care and treatment
CD3
CD3 antigen
CD7
CD7 antigen
Cell surface
Cell therapy
Clinical trials
Correspondence
Cytokines
Genomes
Genomics
Graft versus host disease
Hematology
Humans
Immunotherapy, Adoptive
Leukemia
Leukemia, T-Cell
Lymphocytes
Lymphocytes T
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Lymphomas
Malignancy
Neurotoxicity
Oncology
Protein expression
Proteins
Response rates
Stem cells
T cell leukemia
T cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-023-01406-8